Asymmetric catalysis in the pharmaceutical industry
Asymmetric catalysis in the pharmaceutical industry
复制标题
DOI：
10.1002/anie.200330072
复制
发表时间：
2004-01-01
影响因子：
16.6
通讯作者：
Watson, TJN
中科院分区：
文献类型：
--
作者：
Hawkins, JM;Watson, TJN
从化学角度来看最好的催化剂不一定是从整体经济角度来看最好的催化剂。在坎恶曲的竞争方法中，用于不对称氢化的最具选择性的催化剂（参见方案）并不是最终选择的催化剂。讨论了制药工业在大规模合成候选药物和商业药物中应用不对称催化的限制。
The best catalyst from a chemical perspective is not necessarily the best catalyst from an overall economic perspective. In competing approaches to candoxatril the most selective catalyst for the asymmetric hydrogenation (see scheme) was not the one ultimately chosen. The constraints of the pharmaceutical industry are discussed with regard to the application of asymmetric catalysis to the large‐scale synthesis of drug candidates and commercial drugs.